Carter Gould
Stock Analyst at Barclays
(2.57)
# 1,333
Out of 4,412 analysts
146
Total ratings
51.65%
Success rate
-1.55%
Average return
Main Sectors:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $51 → $43 | $44.85 | -4.12% | 10 | Apr 26, 2024 | |
| BIIB Biogen | Maintains: Equal-Weight | $215 → $200 | $208.90 | -4.26% | 21 | Apr 25, 2024 | |
| SKIL Skillsoft | Maintains: Overweight | $25 → $20 | $7.25 | +175.86% | 5 | Apr 16, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $185 → $195 | $159.62 | +22.17% | 10 | Mar 27, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $62 → $73 | $51.92 | +40.60% | 4 | Feb 29, 2024 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $85 → $80 | $65.42 | +22.29% | 11 | Feb 12, 2024 | |
| MRK Merck & Co. | Maintains: Overweight | $135 → $145 | $131.20 | +10.52% | 8 | Feb 2, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $935 → $1,020 | $883.20 | +15.49% | 10 | Jan 23, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $145 → $150 | $135.99 | +10.30% | 7 | Jan 23, 2024 | |
| LLY Eli Lilly | Maintains: Overweight | $630 → $680 | $733.51 | -7.30% | 8 | Jan 23, 2024 | |
| ALLK Allakos | Maintains: Underweight | $1.5 → $1 | $1.02 | -1.96% | 4 | Jan 17, 2024 | |
| PFE Pfizer | Maintains: Equal-Weight | $34 → $28 | $25.40 | +10.24% | 11 | Dec 14, 2023 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $31 → $12 | $5.26 | +128.14% | 3 | Sep 22, 2023 | |
| AMGN Amgen | Maintains: Underweight | $225 → $210 | $269.98 | -22.22% | 13 | Jul 11, 2023 | |
| ALEC Alector | Maintains: Overweight | $14 → $12 | $5.25 | +128.57% | 2 | May 5, 2023 | |
| GOSS Gossamer Bio | Maintains: Equal-Weight | $2 → $1.5 | $0.67 | +124.55% | 5 | Mar 21, 2023 | |
| VOR Vor Biopharma | Maintains: Overweight | $26 → $15 | $1.69 | +787.57% | 2 | Nov 11, 2022 | |
| MTEM Molecular Templates | Maintains: Overweight | $68 → $15 | $1.71 | +779.77% | 2 | Nov 11, 2022 | |
| APLT Applied Therapeutics | Maintains: Equal-Weight | $2.5 → $2.25 | $4.28 | -47.43% | 4 | Aug 16, 2022 | |
| PAYC Paycom Software | Maintains: Equal-Weight | $392 → $380 | $188.89 | +101.18% | 1 | Jan 20, 2022 | |
| CYTK Cytokinetics | Maintains: Overweight | n/a | $65.34 | - | 1 | Jul 20, 2021 | |
| INCY Incyte | Downgrades: Neutral | n/a | $51.68 | - | 3 | Jan 16, 2019 | |
| VRTX Vertex Pharmaceuticals | Maintains: Neutral | n/a | $397.48 | - | 1 | Jul 26, 2018 |
Bristol-Myers Squibb Company
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $51 → $43
Current: $44.85
Upside: -4.12%
Biogen
Apr 25, 2024
Maintains: Equal-Weight
Price Target: $215 → $200
Current: $208.90
Upside: -4.26%
Skillsoft
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $7.25
Upside: +175.86%
AbbVie
Mar 27, 2024
Maintains: Overweight
Price Target: $185 → $195
Current: $159.62
Upside: +22.17%
Arcellx
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $51.92
Upside: +40.60%
Gilead Sciences
Feb 12, 2024
Maintains: Equal-Weight
Price Target: $85 → $80
Current: $65.42
Upside: +22.29%
Merck & Co.
Feb 2, 2024
Maintains: Overweight
Price Target: $135 → $145
Current: $131.20
Upside: +10.52%
Regeneron Pharmaceuticals
Jan 23, 2024
Maintains: Overweight
Price Target: $935 → $1,020
Current: $883.20
Upside: +15.49%
Neurocrine Biosciences
Jan 23, 2024
Maintains: Overweight
Price Target: $145 → $150
Current: $135.99
Upside: +10.30%
Eli Lilly
Jan 23, 2024
Maintains: Overweight
Price Target: $630 → $680
Current: $733.51
Upside: -7.30%
Allakos
Jan 17, 2024
Maintains: Underweight
Price Target: $1.5 → $1
Current: $1.02
Upside: -1.96%
Pfizer
Dec 14, 2023
Maintains: Equal-Weight
Price Target: $34 → $28
Current: $25.40
Upside: +10.24%
Travere Therapeutics
Sep 22, 2023
Maintains: Overweight
Price Target: $31 → $12
Current: $5.26
Upside: +128.14%
Amgen
Jul 11, 2023
Maintains: Underweight
Price Target: $225 → $210
Current: $269.98
Upside: -22.22%
Alector
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $5.25
Upside: +128.57%
Gossamer Bio
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.67
Upside: +124.55%
Vor Biopharma
Nov 11, 2022
Maintains: Overweight
Price Target: $26 → $15
Current: $1.69
Upside: +787.57%
Molecular Templates
Nov 11, 2022
Maintains: Overweight
Price Target: $68 → $15
Current: $1.71
Upside: +779.77%
Applied Therapeutics
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $4.28
Upside: -47.43%
Paycom Software
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $188.89
Upside: +101.18%
Cytokinetics
Jul 20, 2021
Maintains: Overweight
Price Target: n/a
Current: $65.34
Upside: -
Incyte
Jan 16, 2019
Downgrades: Neutral
Price Target: n/a
Current: $51.68
Upside: -
Vertex Pharmaceuticals
Jul 26, 2018
Maintains: Neutral
Price Target: n/a
Current: $397.48
Upside: -